Collagenase (Xiapex) injection and Manipulation for Dupuytrens contracture surgical technique
Subscribe to get full access to this operation and the extensive Upper Limb & Hand Surgery Atlas.
Learn the Collagenase (Xiapex) injection and Manipulation for Dupuytrens contracture surgical technique with step by step instructions on OrthOracle. Our e-learning platform contains high resolution images and a certified CME of the Collagenase (Xiapex) injection and Manipulation for Dupuytrens contracture surgical procedure.
This is a detailed step by step instruction through an injection of a pretendinous Dupuytren’s cord with collagenase enzyme.
Dupuytren’s contracture is a relatively common condition which causes a histological alteration in a number of fascial structures within the palmar surface of the hand. It is a clinical diagnosis and only rarely when there is a single nodule which has not caused any contracture in the early stages can it be difficult to diagnose. 75% of cases occur in the ulna 2 digits.
There is no current cure for the disease however there are 4 main groups of treatment options to improve contractures. These options are needle fasciotomy, fasciectomy, dermo-fasciectomy and collagenase injections. Within the fasciectomy group terminology becomes confusing with many terms being used synonymously despite original descriptions differing. Examples are focal, segmental and limited fasciectomy. There is also variation in a dermo-fasciectomy with a small fire-break skin grafts or a larger graft covering a clear anatomical section e.g. volar finger between MCPJ and PIPJ creases.
In addition, adjuncts to surgery such as temporary external fixators or salvage options such as amputation are also included in the Dupuytren’s treatment armamentarium.
Collagenase clostridium hostolyticum (XiapexTM in the UK, XiaflexTM in the USA) injections have be used for Dupuytren’s contracture since FDA (food and drug administrations) approval in 2010. Collagenase is an enzyme which breaks down the peptide bonds in the collagen within Dupuytren’s tissue. AUX-I and AUX-II collagenase break the bonds within Type 1 and Type 3 collagen.
The injection is performed either in a clinic or theatre setting without any anaesthetic and then 1-3 days later (by the distributers recommendations). The finger is manipulated under local anaesthetic (LA) and then a review by the hand therapists and a thermoplastic night splint is applied for 3 months.
In July 2017 NICE (National institute for health and care excellence) in the UK produced guidance for use of collagenase in the NHS. This recommended that a palpable cord could be treated if there is moderate disease (MCPJ contracture 30-60 degrees and PIPJ less than 30 degrees) and one injection per treatment session.
A multicentre RCT the DISC trial (Dupuytren’s interventions surgery versus collagenase) began recruiting in the UK in May 2017 and will have a 2 year follow up for fasciectomy versus collagenase completed by October 2021.
Complications include failure of complete correction (common with severe PIPJ disease where the joint capsule and ligaments are contracted), recurrence (very common over time with rates of around 50% at 5 years depending on disease severity, joint involved and amount of correction achieved at manipulation), tendon rupture, neurovascular injury (rare and usually neuropraxia), skin tear during manipulation, pain and swelling post injection, infection, stiffness and allergy to collagenase.
Author: Mr Mark Brewster FRCS (Tr & Orth)
Institution: The Royal Orthopaedic Hospital, Birmingham, UK.
0 of 15 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 15 questions answered correctly
Time has elapsed
Question 1 of 15
Which ONE option describes the % of patients who have Dupuytren’s contracture in which the little and ring finger are effected?CorrectIncorrect
Question 2 of 15
Which ONE option describes the types of collagen cleaved by collagenase – Xiapex?CorrectIncorrect
Question 3 of 15
Which ONE option describes a patient who may be treated with Collagenase within the NiCE guidelines?CorrectIncorrect
Question 4 of 15
Which ONE option describes common complications with collagenase treatment of Dupuytren’s?CorrectIncorrect
Question 5 of 15
Which ONE option names the cord which pulls the neurovascular bundle centrally around the level of the MCPJ crease?CorrectIncorrect
Question 6 of 15
Which ONE option describes the cords which are found running transverse between the webs of the fingers?CorrectIncorrect
Question 7 of 15
Which ONE option describes the vertical fibres which attach to the skin causing pitting?CorrectIncorrect
Question 8 of 15
Which ONE of these is not included in Dupuytren’s Diathisis?CorrectIncorrect
Question 9 of 15
Which ONE option describes the reason severe MCPJ contractures are more easily corrected than severe PIPJ contractures?CorrectIncorrect
Question 10 of 15
Which ONE option is a concerning symptom which should be investigated further?CorrectIncorrect
Question 11 of 15
Which ONE of these is not a contraindication to collagenase injection?CorrectIncorrect
Question 12 of 15
Which ONE option best describes the volume injected for a PIPJ cord?CorrectIncorrect
Question 13 of 15
Which ONE option describes where the XiapexTM guideline suggests is the distal limit of injection for collagenase?CorrectIncorrect
Question 14 of 15
Which ONE option describes the overall recurrence rate at 5 year of >20 degree contracture in the CORDLESS trial?CorrectIncorrect
Question 15 of 15
Which ONE option describes the % of patients who recurred by >20 degree in the CORDLESS trial at 5 years who chose to have further intervention for their Dupuytren’s?CorrectIncorrect